Atopic Dermatitis

Experts treating pediatric atopic dermatitis discuss the pharmacological options for the treatment of pediatric atopic dermatitis.

Expert pediatric dermatologists Elizabeth Swanson, MD, and Joshua Zeichner, MD, discuss the burden of pediatric atopic dermatitis.

Brittany Craiglow, MD; Raj Chovatiya, MD, PhD; and Joshua Zeichner, MD, discuss the presentation of pediatric patients with atopic dermatitis and how to properly assess and diagnose pediatric patients’ atopic dermatitis.

Elizabeth Swanson, MD, and Joshua Zeichner, MD, discuss the psychological factors impacting pediatric patients’ atopic dermatitis.

Joshua Zeichner, MD, and Raj Chovatiya, MD, PhD, dive deep into the pathogenesis of atopic dermatitis and discuss how agents treating atopic dermatitis work.

Joshua Zeichner, MD, and Vikash Oza, MD, discuss characteristics of type 2 inflammation and the impact of itching on pediatric patients with atopic dermatitis.

A recent survey showed correlation between the severity of atopic dermatitis and the negative impacts on family life.

At the SPD 2022 47th Annual Meeting in Indianapolis, Candrice R. Heath, MD, FAAP, FAAD share compelling best practices for treating patients of color with this condition.

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the 2022 Maui Dermatology Conference for PAs & NPs.

At the 2022 Maui Derm NP+PA meeting in Colorado Springs, Colorado, a discussion of the newest biologics and how to "mix and match" medications and algorithms.

James Treat, MD, dives into pediatric patients dealing with alopecia areata, sleep issues in children with atopic dermatitis, and more.

New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.

A recent study showed that patients with atopic dermatitis have a higher prevalence of infertility, highlighting the need for clinicians to be wary of this increased risk and improve the care and management of this patient population.

Amy Paller, MD, sits down to answer important questions on the FDA approval of dupilumab for patients aged 6 months to 5 years.

Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis.

A poster presented at the 2022 Fall Clinical Dermatology Conference for PAs & NPs showed normalization of skin barrier function in patients with moderate to severe atopic dermatitis taking dupilumab, according to the investigators.

Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

It's a hallmark of atopic dermatitis, but isn't always easy to assess. A presentation at the Revolutionizing Atopic Dermatitis meeting looks at available tools.

An abstract presented at the Revolutionizing Atopic Dermatitis meeting discussed the impact of treatment with dupilumab on the quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

What is the relationship between mental disorders and atopic dermatitis? Investigators from a recent study endeavored to find out.

How to prevent, minimize, and treat maskne

Irritated skin in the diaper area may make parents first think of diaper rash, but atopic dermatitis is another possible condition. Knowing the triggers can help determine the correct diagnosis.

Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children at the virtual Maui Derm MP+PA Fall 2021 conference.

Regeneron Pharmaceuticals, Inc. and Sanofi announced safety and efficacy results from LIBERTY AD trial for pediatric patients ages 6 months to 5 years.

A phase 3 trial studies the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis.

A study published in the Journal of the American Academy of Dermatology examined the potential relationship between air pollution and the incidence of atopic dermatitis.

New and forthcoming options bring opportunity for optimizing patient care.

Can probiotics help with atopic dermatitis risk? A meta-analysis offers some answers.